Abstract: This invention provides methods of screening a nuclear transcription factor ligand for the ability to modulate estrogen activation at an AP-1 site.

Abstract: The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The invention includes a method for identifying residues comprising a coactivator binding site for a nuclear receptor of interest. Also included is a method of identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor of interest. Agonists and antagonists of coactivator binding to nuclear receptors also are provided. The invention is exemplified by identification and manipulation of the coactivator binding site of the thyroid receptor (TR), and compounds that bind to this sites. The methods can be applied to other nuclear receptors including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR.

Abstract: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.

Abstract: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.

Abstract: This invention provides methods for modulating gene expression at the transcriptional level. In particular, the methods involve tethering a transcriptional coactivator to a DNA binding domain that is specific for a target nucleic acid sequence and contacting the coactivator with a transcription factor. The transcription factor triggers or represses transcription mediated by the coactivator. Methods for identifying compounds that are able to modulate gene expression are also provided.

Abstract: An expression system for recombinant production of a desired protein comprises CHO cells transformed with a DNA sequence having the desired protein coding sequence under control of the human metallothionein-II promoter. The cells can be maintained on serum-free medium and induced in the presence of an induction mediator. In addition, the system may include an enhancer element and/or a resistance-conferring gene to provide increased levels of expression. The system can process genomic as well as intronless DNA, and is capable of producing proteins which have the same characteristics as those obtained from native sources. Human growth hormone which is indistinguishable from that produced by the pituitary has been thus produced.